Quadrant Biosciences on Capitol Hill - an update from the CEO
I hope everyone is staying safe in these tumultuous times. I wanted to update you on my recent visit to Washington D.C. to engage with key members of Congress and the Executive Branch about Clarifi ASD.
My colleagues from Quadrant and I had the great privilege of speaking with Congressman Chris Smith (R-NJ) and Congressman Mike Doyle (D-PA), the Co-Leaders of the Congressional Autism Caucus, as well as Congresswoman Rosa DeLauro (D-CT), Chairwoman of the House Appropriations Subcommittee on Labor, Health and Human Services, and Education, and Senator Chuck Grassley (R-IA), Chairman of the Senate Finance Committee.
We created awareness about the potential to significantly improve the lives of thousands of Americans by widespread adoption of scalable, highly accurate diagnostic tests for autism. Beyond clinical value, improvements to the diagnostic process can lead to a decrease in the lifetime costs of autism. A cost analysis, independently verified by Avalere Health, estimates the cost savings in education to exceed $13 billion/year and the savings in medical and residential care is expected to exceed $11 billion/year (totaling more than $24 billion/year in taxpayer savings). Needless to say, these figures resonated significantly with the Congresspeople.
What's more, we have been asked to brief the Congressional Autism Caucus, a bipartisan effort that includes over 180 Members of Congress from over 40 states! We are very honored and excited to be afforded this great opportunity to discuss the needs of children with autism and their families with Members of Congress.
Finally, our clinical and basic science research efforts continue to advance in our three areas of focus: Autism Spectrum Disorder, Parkinson’s Disease and Concussion Injuries. Stay tuned for updates on all of these topics in the coming weeks.
As always, please feel free to ask a question on the Wefunder page or contact us directly. And thank you again for your steadfast support!
With kind regards, Rich Founder and CEO Quadrant Biosciences
Wefunder supports three different federal laws that allow startups to raise money legally. To comply with the law, Wefunder Advisors LLC and Wefunder Portal LLC (both owned by Wefunder Inc) also list startups depending on the regulation used.
Legal May 16th 2016
Wefunder Portal LLC
for 390 startups
Wefunder Advisors LLC
for 115 startups
for 3 startups
Curious how well the companies have done? Or how many raised follow-on financing?
Some fine print: 1) These numbers include startups currently live on Wefunder if they pass their minimum target. 2) Some startups use two different laws at the same time (i.e., Regulation D and Regulation Crowdfunding).
Join 687,663 investors who funded 477 startups with over $174 million1
wefunder.com/updates/125364-quadrant-biosciences-on-capitol-hill-an-update-from-the-ceo is managed by
Wefunder Inc. runs wefunder.com and is the parent company of Wefunder Advisors LLC and Wefunder Portal LLC. Wefunder Advisors is an exempt reporting adviser that advises SPVs used in Reg D offerings. Wefunder Portal is a funding portal (CRD #283503) that operates sections of wefunder.com where some Regulation Crowdfunding offerings are made.
Wefunder, Inc. operates sections of wefunder.com where some Regulation D and A offerings are made. Wefunder, Inc. is not regulated as either a broker-dealer or funding portal and is not a member of FINRA.
You may also view our Privacy Notice.